RecruitingPhase 1NCT04678648

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

Studying Astrocytoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
RasCal Therapeutics, Inc.
Principal Investigator
Michael Mann, MD, MD
RasCal Therapeutics, Inc.
Intervention
RSC-1255 Dose Escalation(drug)
Enrollment
134 target
Eligibility
18 years · All sexes
Timeline
20212027

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04678648 on ClinicalTrials.gov

Other trials for Astrocytoma

Additional recruiting or active studies for the same condition.

See all trials for Astrocytoma

← Back to all trials